Portal de Periódicos da CAPES

Proline Dehydrogenase As An Indication for Treatment Response in Sera of Patients With Breast Cancer

2023; Volume: 15; Issue: 1 Linguagem: Inglês

10.21608/eajbsc.2023.291734

2090-083X

Sara Al-Bayate, Rafah Razooq Hameed Al-Samarrai, Ahmed Zuhair Alsammarraie,

Advanced Breast Cancer Therapies

Breast cancer-BC is a type of cancer that develops in the breast tissue.It is the most common cancer among women worldwide.So the current study aimed to evaluate the activity of serum proline dehydrogenase-PRODH and some biochemical parameters in sera of women with breast cancer as an indication for treatment response.Ninety serum samples were collected from women with and without breast cancer-BC, 30 samples were collected from women with BC(newly diagnosed cases) as the first group-G1 and 30 samples were collected from patients with BC after undergoing chemotherapy as second group-G2.While a 3rd group is a control group C which was collected from 30 healthy women.The study includes the determination of PRODH, Metaloendopeptidase-MME, Catalase-CAT and Glutathione-S-transferase -GST activity and also the determination of the level of cancer antigen-15-3-CA15-3 and peroxynitrite -PNT in sera of groups under investigation.The results of the study indicate: In G1 the level of CA15-3 and CAT significantly elevated(P≤0.05),with no significant difference in PRODH, MME, and GST and a significant reduction in the level of PNT as compared with G2 and C, While in G2 the level of PRODH, MME, CAT, and PNT significant difference as a response for treatment, with no significant difference in CA15-3 and GST as compared with G1and C.We can conclude that the enzymes (PRODH, MME, and GST ) may serve as a potential therapeutic target for breast cancer.